Keith Wayne Ward - 14 Dec 2021 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
14 Dec 2021
Net transactions value
$0
Form type
4
Filing time
16 Dec 2021, 17:50:43 UTC
Next filing
09 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Director Option Grant (Right to Buy) Award $0 +250,000 $0.000000 250,000 14 Dec 2021 Common Stock 250,000 $0.0580 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option grant shall be exercisable for a price of $0.058 per Option Share for ten years from December 14, 2021 (the "Grant Date") and the Options will vest in equal monthly installments over the one year period from the Grant Date.